Biotech Values

[jq1234]

PPAR: GSK had done extensive research in PPAR isoforms, published some of them, for example,

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940322/pdf/PPAR2007-97125.pdf

But nothing has come out since Avandia.

After Roche discontinued PPAR-alpha/gamma Aleglitazar in ph3 due to safety and lack of efficacy last year,

http://www.roche.com/media/media_releases/med-cor-2013-07-10.htm

Many wondered whether that was end of PPAR:

http://pipeline.corante.com/archives/2013/07/11/the_last_ppar_compound.php

Overall, this class of drug is under a cloud, FDA gave a complete summary of PPAR development issues here,

http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm119071.pdf

http://lecorpdocs.le-corp.net/wp-content/uploads/2012/04/ALL%20ARTICLES/El-Hage%20PPAR%20Slideshow.pdf

Again, this doesn't mean every compound in this class will have issue, but it falls into questionable until proven in clinic category. At least to me, it is interesting only when valuation is low.